These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7927981)

  • 1. AIDS vaccines and adjuvant formulations.
    Cernescu CE
    Int J Immunopharmacol; 1994; 16(5-6):369-79. PubMed ID: 7927981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
    Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adjuvants in retroviral vaccines.
    Vogel FR
    Int J Immunopharmacol; 1995 Feb; 17(2):85-90. PubMed ID: 7657411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants for HIV vaccines.
    Rao M; Alving CR
    Curr Opin HIV AIDS; 2016 Nov; 11(6):585-592. PubMed ID: 27607594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of HIV vaccines.
    Graham BS
    Annu Rev Med; 2002; 53():207-21. PubMed ID: 11818471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine adjuvant formulations: a pharmaceutical perspective.
    Brito LA; Malyala P; O'Hagan DT
    Semin Immunol; 2013 Apr; 25(2):130-45. PubMed ID: 23850011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel adjuvant strategies for experimental malaria and AIDS vaccines.
    Alving CR; Detrick B; Richards RL; Lewis MG; Shafferman A; Eddy GA
    Ann N Y Acad Sci; 1993 Aug; 690():265-75. PubMed ID: 8368743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants.
    Sasaki S; Tsuji T; Asakura Y; Fukushima J; Okuda K
    Anticancer Res; 1998; 18(5D):3907-15. PubMed ID: 9854503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel adjuvants & delivery vehicles for vaccines development: a road ahead.
    Mohan T; Verma P; Rao DN
    Indian J Med Res; 2013 Nov; 138(5):779-95. PubMed ID: 24434331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
    AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes as carriers for vaccines.
    Wassef NM; Alving CR; Richards RL
    Immunomethods; 1994 Jun; 4(3):217-22. PubMed ID: 7820452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New hope for an AIDS vaccine.
    Robinson HL
    Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic adjuvants for modern vaccine formulations.
    Vogel FR
    Ann N Y Acad Sci; 1995 May; 754():153-60. PubMed ID: 7625649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.
    Chin'ombe N; Ruhanya V
    Pan Afr Med J; 2015; 20():386. PubMed ID: 26185576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and testing of AIDS vaccines.
    Koff WC; Hoth DF
    Science; 1988 Jul; 241(4864):426-32. PubMed ID: 3293212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.
    Gao Y; Wijewardhana C; Mann JFS
    Front Immunol; 2018; 9():345. PubMed ID: 29541072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.